DK0564461T3 - Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil - Google Patents
Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertilInfo
- Publication number
- DK0564461T3 DK0564461T3 DK91918565.2T DK91918565T DK0564461T3 DK 0564461 T3 DK0564461 T3 DK 0564461T3 DK 91918565 T DK91918565 T DK 91918565T DK 0564461 T3 DK0564461 T3 DK 0564461T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnf
- xanthine
- antibody
- range
- xanthine derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909023783A GB9023783D0 (en) | 1990-11-01 | 1990-11-01 | Pharmaceutical product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0564461T3 true DK0564461T3 (da) | 1997-01-20 |
Family
ID=10684716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91918565.2T DK0564461T3 (da) | 1990-11-01 | 1991-10-30 | Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0564461B1 (da) |
| JP (1) | JP3468515B2 (da) |
| KR (1) | KR930701970A (da) |
| AT (1) | ATE146971T1 (da) |
| AU (1) | AU653180B2 (da) |
| CA (1) | CA2094154A1 (da) |
| DE (1) | DE69123984T2 (da) |
| DK (1) | DK0564461T3 (da) |
| ES (1) | ES2096662T3 (da) |
| GB (1) | GB9023783D0 (da) |
| GR (1) | GR3022210T3 (da) |
| HU (1) | HUT70267A (da) |
| NO (1) | NO931580D0 (da) |
| WO (1) | WO1992007585A1 (da) |
| ZA (1) | ZA918712B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| WO1994008619A1 (en) * | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Treatment of autoimmune and inflammatory disorders |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US6770279B1 (en) | 1992-10-08 | 2004-08-03 | The Kennedy Institute Of Rheumatology | TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis |
| DK0701571T3 (da) * | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antistoffragmenter til terapi |
| WO1995013075A1 (en) * | 1993-11-12 | 1995-05-18 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
| DE4411660A1 (de) * | 1994-04-05 | 1995-10-12 | Hoechst Ag | Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung |
| JP2001513754A (ja) * | 1996-12-06 | 2001-09-04 | アムジェン インコーポレイテッド | Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療 |
| EP1352656A3 (en) * | 1996-12-06 | 2004-02-04 | Amgen Inc. | Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
| US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6395273B1 (en) * | 1998-06-10 | 2002-05-28 | Promega Corporation | Prevention and treatment of inflammatory bowel disease |
-
1990
- 1990-11-01 GB GB909023783A patent/GB9023783D0/en active Pending
-
1991
- 1991-10-30 DK DK91918565.2T patent/DK0564461T3/da active
- 1991-10-30 KR KR1019930701250A patent/KR930701970A/ko not_active Application Discontinuation
- 1991-10-30 CA CA002094154A patent/CA2094154A1/en not_active Abandoned
- 1991-10-30 DE DE69123984T patent/DE69123984T2/de not_active Expired - Fee Related
- 1991-10-30 WO PCT/GB1991/001907 patent/WO1992007585A1/en active IP Right Grant
- 1991-10-30 JP JP51773591A patent/JP3468515B2/ja not_active Expired - Lifetime
- 1991-10-30 ES ES91918565T patent/ES2096662T3/es not_active Expired - Lifetime
- 1991-10-30 HU HU9301093A patent/HUT70267A/hu unknown
- 1991-10-30 AT AT91918565T patent/ATE146971T1/de not_active IP Right Cessation
- 1991-10-30 AU AU87583/91A patent/AU653180B2/en not_active Ceased
- 1991-10-30 EP EP91918565A patent/EP0564461B1/en not_active Expired - Lifetime
- 1991-11-01 ZA ZA918712A patent/ZA918712B/xx unknown
-
1993
- 1993-04-30 NO NO931580A patent/NO931580D0/no unknown
-
1997
- 1997-01-03 GR GR960403495T patent/GR3022210T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9301093D0 (en) | 1993-07-28 |
| AU653180B2 (en) | 1994-09-22 |
| ATE146971T1 (de) | 1997-01-15 |
| NO931580D0 (no) | 1993-04-30 |
| ES2096662T3 (es) | 1997-03-16 |
| DE69123984D1 (de) | 1997-02-13 |
| EP0564461A1 (en) | 1993-10-13 |
| EP0564461B1 (en) | 1997-01-02 |
| KR930701970A (ko) | 1993-09-08 |
| DE69123984T2 (de) | 1997-05-22 |
| AU8758391A (en) | 1992-05-26 |
| JPH06502629A (ja) | 1994-03-24 |
| HUT70267A (en) | 1995-09-28 |
| CA2094154A1 (en) | 1992-05-02 |
| JP3468515B2 (ja) | 2003-11-17 |
| ZA918712B (en) | 1992-09-30 |
| GB9023783D0 (en) | 1990-12-12 |
| GR3022210T3 (en) | 1997-04-30 |
| WO1992007585A1 (en) | 1992-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69724451D1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
| DK0564461T3 (da) | Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil | |
| NO914541L (no) | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner | |
| NO985150D0 (no) | Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft | |
| ES2113980T3 (es) | Ligandos solubles para cd40. | |
| DK0751781T3 (da) | Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme | |
| NO20053862L (no) | Aktiv immunisering for a danne antistoffer mot loselig A-beta | |
| DK0536275T3 (da) | Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf | |
| DE68927671D1 (de) | Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier | |
| IL103981A0 (en) | Pharmaceutical compositions for treatment of multiple sclerosis | |
| WO1998026747A3 (en) | Superantigen based methods and compositions for treatment of diseases | |
| ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
| DK0957903T3 (da) | Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser | |
| DE69229050D1 (de) | Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen | |
| ATE234111T1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| DE68921979T2 (de) | Antikörper für die antilymphozyten-antikörpertherapie. | |
| ATE349468T1 (de) | Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung | |
| DK407383A (da) | Diaminopyrimidiner, fremgangsmaader til deres fremstilling, deres anvendelse og mellemprodukter anvendelige ved forbindelsernes fremstilling | |
| EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
| NZ328940A (en) | Methods and use t cell epitopes of lol p v ryegrass pollen antigens | |
| NO961423D0 (no) | Oligopeptider avledet fra C-reaktive proteinfragmenter | |
| NO970165L (no) | Kortikotropin frigivningsfaktor-bindingsprotein inhibitorer og deres anvendelse | |
| GB2233559A (en) | Antibodies for use in antilymphocyte antibody therapy |